知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

47 records (took 0.16 seconds)

    Polyethylene glycol derivatives, modified peptides and production thereof
    2.
    发明授权
    Polyethylene glycol derivatives, modified peptides and production thereof 失效
    聚乙二醇衍生物，修饰肽及其制备

    公开(公告)号：US5214131A

    公开(公告)日：1993-05-25

    申请号：US798138

    申请日：1991-11-26

    Applicant: Akihiko Sano ,  Hiroo Maeda ,  Yoshiyuki Kai ,  Keiichi Ono

    Inventor： Akihiko Sano ,  Hiroo Maeda ,  Yoshiyuki Kai ,  Keiichi Ono

    IPC: C07K1/06 ,  C07K1/107 ,  C08G65/323 ,  C08G65/329 ,  C08G65/334

    CPC classification number: C07K1/064 ,  C07K1/1077 ,  C08G65/323 ,  C08G65/329 ,  C08G65/3346

    Abstract: A polyethylene glycol derivative of the formula ##STR1## wherein R represents a lower alkyl and n represents an optional positive integer which renders the average molecular weight of the polyethylene glycol moiety about 1,000 to 12,000, a peptide modified by said polyethylene glycol derivative and a method for production thereof. The polyethylene glycol derivative (I) is capable of modifying the guanidino groups in peptides. The peptides modified by the polyethylene glycol derivative (I) are extremely stable, are considerably delayed in biological clearance (i.e. the durability is extended) and exhibit their physiological activities effectively over the long period.

    Abstract translation: 式（I）的聚乙二醇衍生物，其中R表示低级烷基，n表示任选的正整数，其使得聚乙二醇部分的平均分子量为约1,000至12,000，由所述聚乙二醇衍生物修饰的肽 及其制造方法。 聚乙二醇衍生物（I）能够改变肽中的胍基。 由聚乙二醇衍生物（I）改性的肽是非常稳定的，生物清除率（即耐久性延长）显着延迟，并且在长时间内有效地表现出其生理活性。

    Synthesis of a derivative of GRF and intermediate peptides
    5.
    发明授权
    Synthesis of a derivative of GRF and intermediate peptides 失效
    GRF和中间体肽衍生物的合成

    公开(公告)号：US4774319A

    公开(公告)日：1988-09-27

    申请号：US119279

    申请日：1987-11-09

    Applicant: Keiichi Ono ,  Yoshiyuki Kai ,  Yoshiaki Takebayashi ,  Akihiko Sano ,  Kazushi Suwa

    Inventor： Keiichi Ono ,  Yoshiyuki Kai ,  Yoshiaki Takebayashi ,  Akihiko Sano ,  Kazushi Suwa

    IPC: A61K38/00 ,  C07K14/60 ,  C07K7/06 ,  C07K7/08 ,  C07K7/10

    CPC classification number: C07K14/60 ,  A61K38/00 ,  Y02P20/55 ,  Y10S930/12

    Abstract: A process for the manufacture of a polypeptide (I) having the formula: ##STR1## which comprises steps of: (a) coupling, successively and in the order of the sequence of the polypeptide (I), the four protected fragments A, B, C and D or five protected fragments A, B, C, E and F,said fragment A by the formula, Leu-Gin-Asp-Ile-Met-Ser-Arg-NH.sub.2said fragment B by the formula, Gln-Leu-Ser-Ala-Arg-Lys-Leusaid fragment C by the formula, Arg-Lys-Val-Leu-Glysaid fragment D by the formula, Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyrsaid fragment E by the formula, Ile-Phe-Thr-Asn-Ser-Tyrand said fragment F by the formula, Tyr-Ala-Asp-Ala being represented, respectively, and(b) eliminating, at the end of sequence, all the protecting groups to provide the polypeptide (I) which is active on the stimulation of the release of the growth hormone and thus is very useful as medicine for treatment of growth hormone deficiency disease and the like.

    Abstract translation: 一种制备具有下式的多肽（I）的方法：其包括以下步骤：（a）依次和按照多肽（I ），四个保护的片段A，B，C和D或五个保护的片段A，B，C，E和F，所述片段A通过式Leu-Gin-Asp-Ile-Met-Ser-Arg-NH2表示 片段B由式Gln-Leu-Ser-Ala-Arg-Lys-Leu表示，由式Arg-Lys-Val-Leu-Gly表示的片段C表示下式的Tyr-Ala-Asp-Ala- Ile-Phe-Thr-Asn-Ser-Tyr分别表示分子式为Ile-Phe-Thr-Asn-Ser-Tyr的片段E和由式Tyr-Ala-Asp-Ala表示的所述片段F，以及 （b）在序列结束时，除去所有保护基以提供在刺激生长激素释放方面具有活性的多肽（I），因此作为治疗生长激素缺乏症的药物非常有用， 类似。

    Safety cabinet
    6.
    发明授权
    Safety cabinet 有权
    安全柜

    公开(公告)号：US08382873B2

    公开(公告)日：2013-02-26

    申请号：US13429832

    申请日：2012-03-26

    Applicant: Keiichi Ono

    Inventor： Keiichi Ono

    IPC: B01D46/00

    CPC classification number: F24F7/007 ,  A47B9/00 ,  A47B81/00 ,  A47B2200/0019 ,  B08B15/023 ,  B25H1/20 ,  F24F3/1607 ,  Y10S55/18

    Abstract: A safety cabinet can adapt to variations in body height of a worker or user. The safety cabinet prevents various bacteria from proceeding from the outside of the safety cabinet into a working space of the safety cabinet and prevents bacteria or viruses from proceeding from the working space to the outside of the safety cabinet irrespective of a change in opening area of a front opening. A flow velocity of clean air supplied into the working space and a flow velocity of the air flowing through the front opening are set in accordance with a size of the front opening to maintain physical isolation and prevent contamination. The size of the front opening of the safety cabinet is adjustable.

    Abstract translation: 安全柜可以适应工作人员或使用者身高的变化。 安全柜防止各种细菌从安全柜的外部进入安全柜的工作空间，并防止细菌或病毒从工作空间进入安全柜的外部，而不管开启面积如何变化 前开口 供给到工作空间的清洁空气的流速和流过前开口的空气的流速根据前开口的尺寸设定，以保持物理隔离并防止污染。 安全柜的前开口尺寸可调。

    Safety cabinet for antibiohazard
    7.
    发明申请
    Safety cabinet for antibiohazard 有权

    公开(公告)号：US20060150593A1

    公开(公告)日：2006-07-13

    申请号：US11362848

    申请日：2006-02-28

    Applicant: Keiichi Ono

    Inventor： Keiichi Ono

    IPC: B01D46/00

    CPC classification number: B01L1/04 ,  B01L2200/082 ,  B01L2300/0681 ,  B08B15/023 ,  B08B2215/003 ,  F24F3/1607 ,  Y10S55/18 ,  Y10S55/29 ,  Y10S55/46

    Abstract: A safety cabinet which can prevent contaminated air from leaking from a working space through the periphery of a front shutter, and which can prevent outside air from entering the working space has a peripheral structure part surrounding the working space formed with air suction ports in a part opposed to the inner surface of the front shutter connected to a negative pressure passage formed outside of the working space. The negative pressure passage guides air sucked through the air suction ports from the inside and the outside of the working space, toward a filter for purification of the air.

    Process for producing eburnane derivatives
    9.
    发明授权
    Process for producing eburnane derivatives 失效
    生产伊本恩衍生物的方法

    公开(公告)号：US4316028A

    公开(公告)日：1982-02-16

    申请号：US93606

    申请日：1979-11-13

    Applicant: Junki Katsube ,  Keiichi Ono ,  Hajime Kawakami

    Inventor： Junki Katsube ,  Keiichi Ono ,  Hajime Kawakami

    IPC: C07D461/00 ,  C07D471/14

    CPC classification number: C07D471/14 ,  C07D461/00

    Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is a C.sub.1 -C.sub.6 alkyl group and R is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and their salts, which are useful as cerebral vasodilator; and a compound of the formula: ##STR2## wherein R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.3 is a hydrogen atom or the formula: --CO.sub.2 R.sup.1 (R.sup.1 is a C.sub.1 -C.sub.6 alkyl group) and W is an oxygen atom, an imino group or ##STR3## but not an imino group in case that R.sup.3 is a hydrogen atom, which are intermediates of the compound (I), useful per se as cerebral vasodilator and/or antihypertensive agents.

    Abstract translation: 下式的化合物：其中R1是C1-C6烷基，R是氢原子或C1-C6烷基，它们的盐可用作脑血管扩张剂; 和下式的化合物：其中R 2是氢原子或C 1 -C 6烷基，R 3是氢原子或式-CO 2 R 1（R 1是C 1 -C 6烷基）和W 在R3是氢原子的情况下是氧原子，亚氨基或亚氨基，而不是亚氨基，它是作为脑血管扩张剂和/或抗高血压药物的化合物（I）的中间体。

    Butyrophenone compounds
    10.
    发明授权
    Butyrophenone compounds 失效
    丁基苯酚化合物

    公开(公告)号：US4303663A

    公开(公告)日：1981-12-01

    申请号：US795145

    申请日：1977-05-09

    Applicant: Kikuo Sasajima ,  Keiichi Ono ,  Masaru Nakao ,  Hisao Yamamoto

    Inventor： Kikuo Sasajima ,  Keiichi Ono ,  Masaru Nakao ,  Hisao Yamamoto

    IPC: C07D295/10 ,  A61K31/435 ,  A61K31/443 ,  A61K31/445 ,  A61K31/451 ,  A61P9/12 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P25/20 ,  A61P29/00 ,  C07D211/14 ,  C07D211/52 ,  C07D405/06 ,  C07D471/10

    CPC classification number: C07D211/52

    Abstract: Butyrophenone compounds having excellent psychotropic activities represented by the formula: ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 is a lower alkyl group, and Z is a group of either one of the formulae: ##STR2## (wherein the dotted line indicates the optional presence of an additional single bond linkage, R.sup.3 is a hydrogen atom or a hydroxyl group but only when said additional single bond linkage is not present and R.sup.4 is a hydrogen atom or a phenyl or benzyl group optionally substituted with one or two substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy and trifluoromethyl on the benzene ring (except monohalophenyl)), ##STR3## (wherein the dotted line indicates the optional presence of an additional single bond linkage, R.sup.5 is a hydrogen atom or a lower alkyl group and R.sup.6 and R.sup.7 are each a hydrogen atom, a halogen atom or a lower alkyl group), ##STR4## (wherein R.sup.8 is a hydrogen atom or a lower alkyl group and R.sup.9 is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group), ##STR5## (wherein R.sup.10 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a trifluoromethyl group), or ##STR6##

Patent Agency Ranking